

Microbiology Spectrum

Clonal spread of carbapenem-resistant Klebsiella pneumoniae ST11 in Chinese pediatric patients

Xiong Liu, Kaiying Wang, Jiali Chen, Jing-Wen Lyu, Jinhui Li, Qichao Chen, Yanfeng Lin, Benshun Tian, Hongbin Song, Peng Li, and Bing Gu

Corresponding Author(s): Peng Li, Chinese PLA Center for Disease Control and Prevention

Review Timeline: Submission Date: May 24, 2022

Editorial Decision:

Revision Received:

Editorial Decision:

September 26, 2022

Editorial Decision:

October 19, 2022

Revision Received:

October 24, 2022

Accepted: November 4, 2022

Editor: Maria De Francesco

Reviewer(s): Disclosure of reviewer identity is with reference to reviewer comments included in decision letter(s). The following individuals involved in review of your submission have agreed to reveal their identity: Erika Scaltriti (Reviewer #2); Alaa Abouelfetouh (Reviewer #3)

Transaction Report:

(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.)

DOI: https://doi.org/10.1128/spectrum.01919-22

1st Editorial Decision June 24,

20221

June 24, 2022

Dr. Peng Li Chinese PLA Center for Disease Control and Prevention DONGDA street 20# Beijing China

Re: Spectrum01919-22 (Clonal spread of carbapenem-resistant Klebsiella pneumoniae ST11 in Chinese pediatric patients)

Dear Dr. Peng Li:

Thank you for submitting your manuscript to Microbiology Spectrum. When submitting the revised version of your paper, please provide (1) point-by-point responses to the issues raised by the reviewers as file type "Response to Reviewers," not in your cover letter, and (2) a PDF file that indicates the changes from the original submission (by highlighting or underlining the changes) as file type "Marked Up Manuscript - For Review Only". Please use this link to submit your revised manuscript - we strongly recommend that you submit your paper within the next 60 days or reach out to me. Detailed instructions on submitting your revised paper are below.

Link Not Available

Below you will find instructions from the Microbiology Spectrum editorial office and comments generated during the review.

ASM policy requires that data be available to the public upon online posting of the article, so please verify all links to sequence records, if present, and make sure that each number retrieves the full record of the data. If a new accession number is not linked or a link is broken, provide production staff with the correct URL for the record. If the accession numbers for new data are not publicly accessible before the expected online posting of the article, publication of your article may be delayed; please contact the ASM production staff immediately with the expected release date.

The ASM Journals program strives for constant improvement in our submission and publication process. Please tell us how we can improve your experience by taking this quick <u>Author Survey</u>.

Sincerely,

Maria De Francesco

Editor, Microbiology Spectrum

Journals Department American Society for Microbiology 1752 N St., NW Washington, DC 20036 E-mail: spectrum@asmusa.org

Reviewer comments:

Reviewer #1 (Comments for the Author):

Extensive work done.

Kindly review the methodology on "Bacterial isolation and antimicrobial susceptibility testing".

What were the hand hygiene audit results for the wards?

Reviewer #2 (Comments for the Author):

Liu and colleagues describe the clonal spread of carbapenem-resistant Klebsiella pneumoniae ST11 in Chinese pediatric patients throught an extended genomic analysis including phylogeny and mobile element content (antibiotic resistance and virulence genes). Results, in particular the use of phylodynamics in outbreak context, are interesting and this paper is an example of the use of multiple genomic tools to understand outbreak dynamics, in particular for Klebsiella pneumoniae in children hospital context. Apart from these aspects, many formulations and statements are inadequate (see section "Technical and content comments").

Regarding the style, the manuscript would benefit from review by a native speaker.

Reviewer #3 (Comments for the Author):

The study investigates the population structure and phylogeny of 98 Klebsiella pneumoniae isolates obtained from pediatric patients in a Chinese hospital between February 2018 and May 2019. The authors reported the clonal spread of KPC-2 producing ST11 K. pneumoniae strains that were clustered into 2 clades. The study described the plasmid content in the 2 clades complete with resistance genes. The authors used these findings to explain the higher transmissibility among clade 1 isolates relative to clade 2 isolates. The study calls for a wider use of genomic tools to identify outbreaks.

Minor comments were observed:

The manuscript needs minor English revision and editing.

- -Line 64: Would the authors please explain the importance of carbapenem as last resort agent in the treatment and hence the global concern as a result of carbapenem resistance development?
- -Line 117: was the DNA library prepared at the sequencing company? Please give some details about Illumina library prep.
- -Line 124-125: Would the authors please give the details of quality check and trimming of the reads?
- -Would the authors give more details about Fig. 3c as it is not clear how they inferred the substitutions per site per year from the figure.
- -Lines 297-297: Fosfomycin and macrolide susceptibility data are not shown in the table.
- -Line 300: Do the authors mean a statistically significant difference?
- -Lines 304-306: The authors would better comment on the almost complete absence of these genes in the ST11 strains.
- -Line 306: The authors would better specify that they mean IncFII.pHN7A8. 1
- -Line 306-308: "All ST11 strains carried the ColRNAI and IncFII plasmid replicons, which were highly correlated with the presence of blaKPC-2, rmtB, and blaTEM-1B genes" the isolates also carried blaSHV.11_1, blaSHV.155_1 as well as fosA_3 coding for Fosfomycin resistance and oqxA_1 and oqxB_1 coding for fluoroquinolone resistance.
- -Line 308: Looks like only 2 clade 1 strains (and not 3) co-carried blaKPC-2 and mcr-9.
- -Line 310: Looks like the three mcr-9 positive strains carried the pKPC.CAV1321_1 and not repB_KLEB_VIR plasmid replicon. Lines 311-313: the same can be said about ST76 strains and IncX3_1 plasmid replicon and blaNDM.1_1, blaSHV.12_1, fosA_3, ogxA_1 and ogxB_1.

Would the authors please comment on Fig 5B at the end of the results? From Fig 3D and Fig 5B, it seems that strain xz163 evolved from a distant parent xz061 and acquired a 4th plasmid then further evolved to xz168 and xz181.

Lines 314-316: Please mention Additional file 8 Figure S6 here.

Lines 371-372: Figures 3D and 3E show the transmission of clade 1 but not clade 2, so unless the authors are referring to other figures here, would they just mention that these results are not shown?

Staff Comments:

Preparing Revision Guidelines

To submit your modified manuscript, log onto the eJP submission site at https://spectrum.msubmit.net/cgi-bin/main.plex. Go to Author Tasks and click the appropriate manuscript title to begin the revision process. The information that you entered when you first submitted the paper will be displayed. Please update the information as necessary. Here are a few examples of required updates that authors must address:

- Point-by-point responses to the issues raised by the reviewers in a file named "Response to Reviewers," NOT IN YOUR COVER LETTER.
- Upload a compare copy of the manuscript (without figures) as a "Marked-Up Manuscript" file.
- Each figure must be uploaded as a separate file, and any multipanel figures must be assembled into one file.
- Manuscript: A .DOC version of the revised manuscript
- Figures: Editable, high-resolution, individual figure files are required at revision, TIFF or EPS files are preferred

For complete guidelines on revision requirements, please see the journal Submission and Review Process requirements at https://journals.asm.org/journal/Spectrum/submission-review-process. **Submissions of a paper that does not conform to Microbiology Spectrum guidelines will delay acceptance of your manuscript.** "

Please return the manuscript within 60 days; if you cannot complete the modification within this time period, please contact me. If you do not wish to modify the manuscript and prefer to submit it to another journal, please notify me of your decision immediately so that the manuscript may be formally withdrawn from consideration by Microbiology Spectrum.

If your manuscript is accepted for publication, you will be contacted separately about payment when the proofs are issued; please follow the instructions in that e-mail. Arrangements for payment must be made before your article is published. For a complete list of **Publication Fees**, including supplemental material costs, please visit our website.

Corresponding authors may join or renew ASM membership to obtain discounts on publication fees. Need to upgrade your membership level? Please contact Customer Service at Service@asmusa.org.

Thank you for submitting your paper to Microbiology Spectrum.

Technical and content comments:

Line71-72: blaKPC-2 is not a genotype. blaKPC-2, among antibiotic resistence genes, is largely diffused or the most diffused

Line 110-115: the phrase should be simplified

Line 118: the median value shoud be calculated and indicated

Line 119-121: type of flow cell and MinION shoud be added

Line 124: how reads are quality filtered? Please specify Q30 cut off and read lenght cut off (eventually)

Line 130 and subsequent: Version of software should be added after software name, first of references.

Line 130bis: for hybrid assembly, add details on the usage of Unicycler (e.g. conservative mode)

Line 132: Specify databases used with Abricate and if you are starting from reads or assembly (it changes sometimes results)

Line 134 and 138: What SNP pipeline do you use as input for phylogenesis? Is not clear if snippy o roary. Please clarify.

Line 143-147: Add some informations on used models (type of molecular clock and population). Add software name (BEAST?)

Line 149: "Whole genome shotgun project" is not appropriate. Use "whole genome sequences of this project"

Line 175: substitute "performed with "subjected to"

Line 176: "all reads were de novo assembled" substitute "all genomes were de novo assembled starting from reads"

Line 177: substitute "Read mapping to" with "Read mapping against"

Line 183: the final size of the alignment (3790951 bp) is not necessary (see also below)

Line 188: "a structure dominated by" is not enterely correct. Refer to the presence of a major clade of ST 11

Line 226: substitute with "SNPs ranging from 2 to 15 were identified"

Line 229-230: same as Line 183

Line 238: how do you choose this threshold? Do you have references? If yes, please add it. It's a very high number of SNPs and this high threshold may be misleading. This is a very IMPORTANT aspect

Line 241: how do you calculate that temporal signal was strong? (e.g. Tempest software)

Line 270: is not clear if you are working on a non-recombinant dataset or not. Here you mentioned SNPs in recombinant region, but you removed them (line 182).

Line 277: clarify the reason why you mentioned these genes (this gene are under pression in your opinion?). These observations are not well explained.

Line289: replace "clades" with "isolates"

Line 304: "highly correlated" is not clear, explain better. blaKPC-2 is only in this type of plasmids. If yes, supply references

Line 311: replace "plasmid genomes" with "plasmid sequence"

Line 328: Add "probably" first of "indicate that...."

Line 347: remove "the" at the beginning of the line

Line 356-359: this phrase is not clear. Rewrite.

Line 364: the term "obtained" is not appropriate

Line 381-383: this concept is trivial. Rewrite or remove it

Line 389: replace with "plasmids in hospital strains"

Figure 2C: indicate the meaning of dotted lines in the caption

Figure 4: I suggest to visualise only genes that are present at least in one genome to simplify the figure.

Maybe a completed figgure can be put on supplementary.

Response to the reviewers' comments:

2 Reviewer: 1

3 **Point 1:**

1

- 4 Extensive work done.
- 5 Kindly review the methodology on "Bacterial isolation and
- 6 antimicrobial susceptibility testing".
- 7 What were the hand hygiene audit results for the wards?

8 **Response 1:**

- 9 Thanks very much for the reviewer's comments, we have revised the
- methodology on "Bacterial isolation and antimicrobial susceptibility
- 11 testing" in the resubmitted manuscript. (Lines 104-113)

- 13 Hospital infection department had taken strict hand hygiene audit
- measures to control the potential outbreak in the hospital. First,
- pre-screening of carbapenem-resistant Enterobacteriaceae (CRE) in
- sputum samples and rectal swabs were introduced before admission
- 17 to the neonatal medical ward. Second, strict isolation procedures
- were implemented for patients with CRE infection. Third, it was
- 19 necessary for medical staff who contact with patients infected with
- 20 CRE to go through a disinfection procedure. Finally, the neonatal

- 21 medical wards where newborns with CRE infection stayed were
- 22 thoroughly sterilized after the discharge of the patients. The
- 23 sterilized ward left unoccupied for more than two weeks before new
- 24 patients were admitted.

25 Reviewer 2:

26 **Point 2:**

- 27 Liu and colleagues describe the clonal spread of
- 28 carbapenem-resistant Klebsiella pneumoniae ST11 in Chinese
- 29 pediatric patients through an extended genomic analysis including
- 30 phylogeny and mobile element content (antibiotic resistance and
- 31 virulence genes). Results, in particular the use of phylodynamic in
- outbreak context, are interesting and this paper is an example of the
- use of multiple genomic tools to understand outbreak dynamics, in
- 34 particular for Klebsiella pneumoniae in children hospital context.
- 35 Apart from these aspects, many formulations and statements are
- 36 inadequate (see section "Technical and content comments").
- 37 Regarding the style, the manuscript would benefit from review by a
- 38 native speaker.

Response 2:

- 40 Thanks very much for the reviewer's all constructive comments, we
- 41 have carefully revised our manuscript according to the reviewer's

- 42 comments and improved the manuscript by a native speaker. The
- comments raised by reviewer 2 have been responded point by point
- 44 below.
- 45 Technical and content comments:
- 46 **Point 3**
- 47 Line71-72: blaKPC-2 is not a genotype. blaKPC-2, among
- 48 antibiotic resistance genes, is largely diffused or the most
- 49 diffused.
- **Response 3:**
- Sorry, it was a mistake, we have modified the description. "ST11 is
- 52 the most prevalent CRKP sequence type (ST) in China, and bla_{KPC-2}
- is one of the most common drug resistance genes." (Lines 70-72)
- 54 **Point 4:**
- 55 Line 110-115: the phrase should be simplified.
- **Response 4:**
- 57 Thanks very much for the reviewer's comments, we have simplified
- the phrase. "MICs were interpreted according to the CLSI (2021)
- 59 guidelines. The electronic medical records of culture-positive
- 60 children were reviewed retrospectively to obtain demographic and
- clinical data." (Lines 110-113)

- 62 **Point 5:**
- 63 Line 118: the median value should be calculated and indicated.
- 64 **Response 5:**
- Thanks very much for the reviewer's comments, we have revised the
- 66 description in the resubmitted manuscript. "With a median
- 67 sequencing depth of 235.6X." (Lines 122-123)

- 69 We have calculated both the mean and median value of sequencing
- depth, and the two values were very close, the mean sequencing
- depth was 235.8X and the median sequencing depth was 235.6X.
- 72 **Point 6:**
- The 119-121: type of flow cell and MinION should be added.
- 74 **Response 6:**
- 75 Thanks very much for the reviewer's comments, we have added the
- 76 type of flow cell and MinION in the revised manuscript. "The
- 77 nanopore sequencing library was prepared using the SQK- RAD004
- 78 rapid sequencing kit (Oxford Nanotechnology, UK) and sequenced
- on MinION Mk1B R9.4 flowcell in our lab." (Lines 123-126)
- 80 **Point 7:**
- 81 Line 124: how reads are quality filtered? Please specify Q30 cut

- 82 off and read length cut off (eventually)
- 83 **Response 7:**
- Thanks very much for the reviewer's comments, we have descripted
- 85 how reads were quality filtered in the revised manuscript.
- "Sequencing reads were quality filtered using the FastQC v0.11.8
- 87 software, adapters and low-quality reads were removed and filtered
- out using Trimmomatic with default parameters." (Line 128-130)

- We also have specified the Q30 cut off and read length cut off in the
- 91 revised manuscript. "The Q30 cut off was set to 85% and the read
- length cut off was set to longer than 100bp." (Lines 130-131)
- 93 **Point 8:**
- Line 130 and subsequent: Version of software should be added
- 95 after software name, first of references.
- 96 **Response 8:**
- 77 Thanks very much for the reviewer's comments, we have added the
- version of software after the software name as suggested.
- 99 **Point 9:**
- Line 130bis: for hybrid assembly, add details on the usage of
- 101 Unicycler (e.g. conservative mode)

Response 9: 102 103 Thanks very much for the reviewer's comments, we have added details on the usage of Unicycler in the revised manuscript. "hybrid 104 105 assembly was carried out with Unicycler v0.4.8 in normal mode." 106 (Lines 138-140) Point 10: 107 Line 132: Specify databases used with Abricate and if you are 108 starting from reads or assembly (it changes sometimes results) 109 110 **Response 10:** Thanks very much for the reviewer's comments, we have specified 111 the starting and the databases used with Abricate in the revised 112 manuscript. "Resistance, virulence and plasmid profiles were 113 characterized starting from the final assemblies using resfinder, vfdb

116

117

114

115

We also analyzed our short sequencing reads using the SRST2

and plasmidfinder database in ABRicate" (Lines 140-143).

software v0.2.0, which did not change and influence our final 118

results. 119

Point 11: 120

Line 134 and 138: What SNP pipeline do you use as input for 121

122 phylogenesis? Is not clear if snippy o roary. Please clarify.

123 Response 11:

- 124 Thanks very much for the reviewer's comments, we have added the
- 125 SNP pipeline used as input for phylogenesis in the revised
- manuscript.
- "Initially, SNPs across the whole genome were predicted using
- 128 Snippy v4.6.0, the consensus whole genome alignment was used to
- infer a maximum likelihood phylogenetic tree using Raxml-ng
- v1.0.3 implementing with 1000 bootstrap replicates, GTR+ was
- selected as the best evolutionary model by using Modeltest-ng
- 132 v0.1.7" (Lines 147-151)

133 **Point 12:**

- Line 143-147: Add some information on used models (type of
- molecular clock and population). Add software name (BEAST?)

136 Response 12:

- 137 Thanks very much for the reviewer's comments, we have added the
- 138 software name and information on used models in the revised
- 139 manuscript.
- "We used a Bayesian evolutionary analysis to infer a timed
- 141 phylogeny by sampling trees with BEAST v2.4.7 by using the
- 142 concatenated non-recombination alignment and labeled the time tips
- of each strain using the sampled date. We used the GTR substitution

- 144 model with a coalescent constant population size and a strict
- molecular clock rate." (Lines 175-180)
- 146 **Point 13:**
- 147 Line 149: "Whole genome shotgun project" is not appropriate.
- 148 Use "whole genome sequences of this project"
- **149 Response 13:**
- 150 Thanks very much for the reviewer's comments, the manuscript had
- been revised as suggested.
- 152 "Whole genome sequences of this project have been deposited at
- 153 GenBank under accession numbers from JAHQME000000000 to
- 154 JAHQQZ000000000, BioProject ID: PRJNA739673." (Lines
- 155 195-197)
- 156 **Point 14:**
- 157 Line 175: substitute "performed with "subjected to"
- **158 Response 14:**
- 159 Thanks very much for the reviewer's comments, the manuscript had
- been revised as suggested.
- 161 "The 98 isolated K. pneumoniae strains were subjected to short-read
- 162 Illumina sequencing" (Lines 221-222)
- 163 **Point 15:**

- Line 176: "all reads were de novo assembled" substitute "all
- 165 genomes were de novo assembled starting from reads"
- **166 Response 15:**
- 167 Thanks very much for the reviewer's comments, the manuscript had
- been revised as suggested.
- "All genomes were de novo assembled starting from reads." (Lines
- 170 222-223)
- 171 **Point 16:**
- 172 Line 177: substitute "Read mapping to" with "Read mapping
- 173 against"
- **174 Response 16:**
- 175 Thanks very much for the reviewer's comments, the manuscript had
- been revised as suggested.
- "Read mapping against K. pneumoniae reference sequence" (Line
- 178 224)
- 179 **Point 17:**
- Line 183: the final size of the alignment (3790951 bp) is not
- necessary (see also below)
- **182 Response 17:**
- 183 Thanks very much for the reviewer's comments, the manuscript had

- been revised as suggested.
- "Putative recombination loci were further detected and removed, and
- 57,242 variable SNP sites were identified." (Lines 229-230)
- 187 **Point 18:**
- 188 Line 188: "a structure dominated by" is not enterely correct.
- 189 Refer to the presence of a major clade of ST 11
- **190 Response 18:**
- 191 Thanks very much for the reviewer's comments, the manuscript had
- been revised as suggested.
- "Revealed the presence of a major clade of ST11." (Lines 233-234)
- 194 **Point 19:**
- 195 Line 226: substitute with "SNPs ranging from 2 to 15 were
- 196 identified"
- 197 **Response 19:**
- 198 Thanks very much for the reviewer's comments, the manuscript had
- been revised as suggested.
- 200 "Among the eight ST76 strains isolated in 4 different wards from
- July 2018 to January 2019, SNPs ranging from 2 to 15 were
- 202 identified." (Lines 271-272)
- 203 **Point 20:**

204 Line **229-230**: same as Line **183**

Response 20:

- Thanks very much for the reviewer's comments, the manuscript had
- been revised as suggested.
- 208 "To further analyze the highly spatial-temporal associated ST11
- 209 strains, a Bayesian phylogenetic tree based on the
- 210 non-recombination alignment was constructed." (Lines 274-276)

211 **Point 21:**

- 212 Line 238: how do you choose this threshold? Do you have
- references? If yes, please add it. It's a very high number of SNPs
- and this high threshold may be misleading. This is a very
- 215 IMPORTANT aspect

216 **Response 21:**

- 217 Thanks very much for the reviewer's comments.
- First, we have added description on how the threshold was chosen in
- 219 the revised manuscript.
- 220 "The distribution of the pair-wise SNPs distances among strains was
- visualized as showed in the Additional file 5 Figure S3A, the SNP
- cut-off threshold was determined manually by looking at the graph
- 223 and finding that there were two distinctive groups of genome pairs,
- 224 those with less than 35 SNPs and those with more than 35 SNPs,

which allowed us to safely infer that two genomes could be 225 considered as part of the same transmission cluster if their distance 226 227 in number of SNPs was lower than the 35 SNPs threshold value." (Lines161-168) 228 229 Second, we also have found a reference in which pairs of genomes 230 231 within a distance of 35 SNPs were considered as part of the same transmission cluster, and we have added it in the revised manuscript. 232 "Pairs of genomes within a distance of ≤35 SNPs (42) were 233 considered as the same transmission cluster." (Lines 283-284) 234 Point 22: 235 Line 241: how do you calculate that temporal signal was strong? 236 237 (e.g. Tempest software) 238 **Response 22:** 239 Thanks very much for the reviewer's comments, we have added the 240 description on how the temporal signal was calculated in the revised 241 manuscript. "We used a root to tip regression of sampling dates against genetic 242 diversity in TempEst v1.5.3, optimizing the best fit for the root to 243

maximize the determination coefficient R². The slope of the

regression was positive, and the p-value is 0.0006, showing that the

244

genomic data reflect strong temporal signal." (Lines 169-173) 246 Point 23: 247 Line 270: is not clear if you are working on a non-recombinant 248 dataset or not. Here you mentioned SNPs in recombinant region, 249 but you removed them (line 182). 250 251 **Response 23:** Sorry for our unclearly descriptions, in the previous transmission 252 tree analysis part, we were working on the non-recombinant dataset, 253 254 the recombinant regions were removed. But in this part, all genome mutations were analyzed including the recombination and point 255 mutation, thus, 9 mutations introduced by recombination and 143 256 mutations introduced by point mutation were descried. 257 We have added "To investigate the overall genome mutations of 258 259 Clade1 strains, both the recombination and point mutations were in 260 analyzed (Lines 315-316) in the revised manuscript. 261 Point 24: Line 277: clarify the reason why you mentioned these genes (this 262 gene are under pression in your opinion?). These observations 263 264 are not well explained.

Response 24:

Thanks very much for the reviewer's comments.

We have changed "In addition, we identified 5 genes with more than one SNP." with "In this case, a recent population expansion was more likely to happen. All the mutations were annotated according to their genome positions, from which 5 genes were identified with more than one mutation, so we further analyzed the mutation type and function of these 5 genes" (Lines 324-328) in the revised the manuscript.

First, after the identification of the major Clade 1 strains, we further analyzed the 152 SNPs found within them, including both the recombination region mutations and point mutations. All the mutations were annotated according to their genome positions, from which 5 genes were identified with more than one mutation, so we further analyzed the mutation type and function of these 5 genes, which turned out that they were associated with virulence and multidrug efflux system.

Second, most of the genes showed negative Tajima's D values (Additional file 6: Figure S4), especially the 5 genes mentioned here which either suggest negative selection or reflect a recent population expansion. In this case, a recent population expansion was more likely to happen, thus it might be hard to infer whether they were

under positive or negative selection pressure. 288 Point 25: 289 Line289: replace "clades" with "isolates" 290 291 **Response 25:** Thanks very much for the reviewer's comments, the manuscript had 292 293 been revised as suggested. "Antimicrobial resistance gene content and plasmid carriage of the 294 outbreak isolates" (Lines 338-339) 295 Point 26: 296 Line 304: "highly correlated" is not clear, explain better. 297 blaKPC-2 is only in this type of plasmids. If yes, supply 298 references 299 **Response 26:** 300 Sorry for our inappropriate description, bla_{KPC-2} was not only in this 301 type of plasmids and we have revised this description in the 302 303 resubmitted manuscript. 304 "All ST11 strains carried the ColRNAI and IncFII plasmid replicons, 305 which appears to be associated with the presence of several

307 **Point 27:**

306

resistance genes" (Lines 355-357)

- Line 311: replace "plasmid genomes" with "plasmid sequence" 308 **Response 27:** 309 Thanks very much for the reviewer's comments, the manuscript had 310 311 been revised as suggested. "The plasmid sequences were further explored using long-read sequencing assemblies." (Lines 376-377) 312 313 Point 28: Line 328: Add "probably" first of "indicate that...." 314 **Response 28:** 315 316 Thanks very much for the reviewer's comments, the manuscript had been revised as suggested. "which probably indicate that strain 317
- 320 **Point 29:**

318

319

- 321 Line 347: remove "the" at the beginning of the line
- **Response 29:**
- 323 Thanks very much for the reviewer's comments, the manuscript had

xz163 had evolved from a distant parent xz061 containing 3

- 324 been revised as suggested. "which is consistent with previous
- 325 results." (Lines 413-414)

plasmids." (Lines 393-395)

326 **Point 30:**

- Line 356-359: this phrase is not clear. Rewrite.
- **Response 30:**
- Thanks very much for the reviewer's comments, we have revised the
- description.
- "Based on the spatio-temporal analysis, it was found that the ST11
- 332 strains were not the most abundant MLST types in the beginning
- 333 during our collection period, the number of ST11 strains had
- increased gradually and eventually it became the most common
- 335 MLST type." (Lines 423-426)
- 336 **Point 31:**
- Line 364: the term "obtained" is not appropriate
- **Response 31:**
- 339 Thanks very much for the reviewer's comments, we have replaced
- "obtained" with "acquired". (Line 431)
- 341 **Point 32:**
- Line 381-383: this concept is trivial. Rewrite or remove it
- **Response 32:**
- 344 Thanks very much for the reviewer's comments, we have removed
- this description as suggested.

Point 33: 346 347 Line 389: replace with "plasmids in hospital strains" **Response 33:** 348 349 Thanks very much for the reviewer's comments, the manuscript had been revised as suggested. "plasmids in hospital strains." (Line 454) 350 351 Point 34: Figure 2C: indicate the meaning of dotted lines in the caption 352 **Response 34:** 353 354 Sorry for causing your confusion, the dotted lines in Figure 2C were meant to highlight the other strains apart from the ST11 between 355 which the pairwise number of SNPs were less than 35. For example, 356 357 in the Pediatric Intensive Care Unit (PICU), two ST716 strains were enclosed with a dotted line circle since 8 SNPs were identified 358 between them indicating that they were also highly clonal. 359 360 The Figure 2 legends had been added with detailed description. "Strains apart from the ST11 between which the pairwise number of 361 362 SNPs were less than 35 were enclosed by dotted lines" (Lines 363 715-717). **Point 35:** 364 Figure 4: I suggest to visualize only genes that are present at 365

- least in one genome to simplify the figure. Maybe a completed figure can be put on supplementary.

 Response 35:
- Thanks very much for the reviewer's comments, all the genes in Figure 4 were present at least in one genome, we had put it on supplementary as Additional file 7: Figure S5.

Reviewer 3:

The study investigates the population structure and phylogeny of 98 Klebsiella pneumoniae isolates obtained from pediatric patients in a Chinese hospital between February 2018 and May 2019. The authors reported the clonal spread of KPC-2 producing ST11 K. pneumoniae strains that were clustered into 2 clades. The study described the plasmid content in the 2 clades complete with resistance genes. The authors used these findings to explain the higher transmissibility among clade 1 isolates relative to clade 2 isolates. The study calls for a wider use of genomic tools to identify outbreaks.

Minor comments were observed:

Point 36:

The manuscript needs minor English revision and editing.

Response 36:

Thanks very much for the reviewer's constructive comments, we have revised the manuscript according to all the reviewers' comments and the manuscript has also been greatly improved and reviewed by a native speaker.

Point 37:

- -Line 64: Would the authors please explain the importance of
- carbapenem as last resort agent in the treatment and hence the
- 393 global concern as a result of carbapenem resistance
- **development?**

Response 37:

Thanks very much for the reviewer's comments. Carbapenems are bactericidal β -lactam antimicrobials with proven efficacy in severe infections caused by extended spectrum β -lactamase (ESBL) producing bacteria. They possess broad spectrum antibacterial activity and have a unique structure that is defined by a carbapenem coupled to a β -lactam ring which confers protection against most β lactamases such as metallo- β -lactamase (MBL) as well as extended spectrum β -lactamases. Consequently, carbapenems are considered one of the most reliable drugs for treating bacterial infections and the emergence and spread of resistance to these antibiotics constitute a major global public health concern. The World Health Organization

- 407 recognizes extended-spectrum β-lactam (ESBL)-producing and
- 408 carbapenem-resistant K. pneumoniae (CRKp) as a critical public
- 409 health threat.
- 410 **Point 38:**
- -Line 117: was the DNA library prepared at the sequencing
- company? Please give some details about Illumina library prep.
- 413 **Response 38:**
- Thanks very much for the reviewer's comments, the DNA library
- was prepared at the sequencing company. We have added detailed
- 416 description about Illumina library preparation in the revised
- 417 manuscript as suggested
- 418 "The DNA library was prepared at the sequencing company. In brief,
- genomic DNA was extracted from bacteria colonies using QIAamp
- 420 DNA Mini Kit (Qiagen, Hilden, Germany) and quantified using
- 421 Qubit fluorometer (Life Technologies, Carlsbad, CA, USA). The
- libraries were constructed using the Nextera XT kit (Illumina Ltd.,
- 423 San Diego, CA, USA) according to the manufacturer's
- recommendations and sequenced in pair-end mode (2 × 150 bp)
- using the Illumina HiSeq 2500 platform at Novogene Company
- 426 (Beijing, China) with a median sequencing depth of 235.6X" (Lines
- 427 115-123)

- **Point 39:** 428 429 -Line 124-125: Would the authors please give the details of quality check and trimming of the reads? 430 431 **Response 39:** 432 Thanks very much for the reviewer's comments, we have added 433 detailed description about quality check and trimming of the reads in 434 the revised manuscript as suggested "Sequencing reads were quality filtered using the FastQC v0.11.8 435 software, adapters and low-quality reads were removed and filtered 436 437 out using Trimmomatic with default parameters, the Q30 cut off was set to 85% and the read length cut off was set to longer than 100bp.". 438 (Lines 128-131) 439 **Point 40:** 440 441 -Would the authors give more details about Fig. 3c as it is not
- -Would the authors give more details about Fig. 3c as it is not clear how they inferred the substitutions per site per year from the figure.

Response 40:

444

Thanks very much for the reviewer's comments. we have added detailed description about how the substitutions per site per year were inferred in the revised manuscript as suggested "Briefly, SNPs were predicted using Snippy v4.6.0, the consensus

whole genome alignment was used to infer a maximum likelihood 449 phylogenetic tree using Raxml-ng v1.0.3. The whole genome 450 451 alignment and maximum likelihood phylogenetic tree were combined to identify and exclude the recombination regions using 452 ClonalFrameML v1.12. A maximum likelihood phylogenetic tree 453 454 based on the non-recombination alignment was constructed using 455 Raxml-ng v1.0.3. Two major clades were identified, and we assessed 456 the correlation between root-to-tip distance and the date of isolation in TempEst v1.5.3. Following the identification of a strong temporal 457 signal in the Clade 1 strains, we ran BEAST v2.4.7 on the 458 459 recombination-filtered chromosomal alignment and used the GTR substitution model with a coalescent constant population size and a 460 461 strict molecular clock rate to infer the substitutions per site per year." (Lines 147-184) 462

463 **Point 41:**

466

- 464 -Lines 297-297: Fosfomycin and macrolide susceptibility data
- are not shown in the table.

Response 41:

Thanks very much for the reviewer's comments, two types of cards were used for susceptibility testing and some representative antibiotics were selected in the study. One of the card types is

- 470 VITEK 2 AST-N335 test kit, the other one is VITEK 2 AST-GN09
- 471 test kit. VITEK 2 AST-N335 test kit include 17 antibiotics (amikacin,
- 472 aztreonam, cefepime, cefoperazone/sulbactam, ceftazidime,
- 473 ciprofloxacin, colistin, doxycycline, levofloxacin, imipenem
- 474 meropenem, minocycline, piperacillin/tazobactam,
- 475 ticarcillin/clavulanic acid, tigecycline, tobramycin,
- 476 sulfamethoxazole). VITEK 2 AST-GN09 test kit include 20
- antibiotics (amikacin, ampicillin, ampicillin/sulbactam, aztreonam,
- cefazolin, cefepime, cefotetan, ceftazidime, ceftriaxone, cefuroxime,
- 479 ciprofloxacin, gentamicin, imipenem, levofloxacin, meropenem,
- 480 nitrofurantoin, piperacillin, piperacillin/tazobactam, tobramycin,
- 481 sulfamethoxazole).
- We have changed the results description of multiple drug resistance
- in the revised manuscript. "Antibiotic susceptibilities of all strains
- 484 were determined, and showed multiple drug resistance to
- aminoglycosides, beta-lactams and fluoroquinolones". (Lines
- 486 341-344)
- 487 **Point 42:**
- 488 -Line 300: Do the authors mean a statistically significant
- 489 difference?
- 490 **Response 42:**

- Thanks very much for the reviewer's comments, we have performed
- 492 Pearson's Chi-squared Test for the strains carried the bla_{KPC-2} gene
- 493 between ST11 and non-ST11 multi-locus sequence types, the
- 494 X-squared = 69.997, p-value < 2.2e-16, indicating a statistically
- 495 significant difference
- We have changed the results description in the revised manuscript.
- 497 "observed a significant difference (p<0.001) in the carbapenem
- 498 resistance gene content between the ST11 and other STs strains"
- 499 (Lines 346-347).
- 500 **Point 43:**
- -Lines 304-306: The authors would better comment on the
- almost complete absence of these genes in the ST11 strains.
- **Response 43:**
- 504 Thanks very much for the reviewer's comments. We have added
- 505 comments in the revised manuscript as suggested. "The almost
- complete absence of these genes in the ST11 strains might be due to
- the absence of the plasmid carrying them." (Lines 353-355)
- 508 **Point 44:**
- -Line 306: The authors would better specify that they mean
- 510 IncFII.pHN7A8._1
- **Response 44:**

- Thanks very much for the reviewer's comments. We have revised the
- description in the resubmitted manuscript. "In addition, two Clade 1
- strains co-carried blaKPC-2 gene and mcr-9 gene which were
- located on IncFII.pHN7A8. 1 plasmid and IncHI2/IncHI2A plasmid
- respectively." (Lines 362-364)
- 517 **Point 45:**
- -Line 306-308: "All ST11 strains carried the ColRNAI and
- 519 IncFII plasmid replicons, which were highly correlated with the
- presence of blaKPC-2, rmtB, and blaTEM-1B genes" the isolates
- also carried blaSHV.11 1, blaSHV.155 1 as well as fosA 3
- coding for Fosfomycin resistance and oqxA_1 and oqxB_1
- 523 coding for fluoroquinolone resistance.
- **Response 45:**
- 525 Thanks very much for the reviewer's comments. We have revised the
- 526 description in the resubmitted manuscript.
- "All ST11 strains carried the ColRNAI and IncFII plasmid replicons,
- 528 which appears to be associated with the presence of several
- 529 resistance genes including blaKPC-2, rmtB, blaTEM-1B,
- 530 blaSHV.11_1, blaSHV.155_1, fosA_3, oqxA_1 and
- oqxB_1(Additional file 7 Figure S5). However, only three genes
- 532 (blaKPC-2, rmtB, and blaTEM-1B) among them were found located

- on the plasmid contigs indicating that they might be located the two
- related plasmids." (Lines 355-362)
- 535 **Point 46:**
- -Line 308: Looks like only 2 clade 1 strains (and not 3)
- 537 **co-carried blaKPC-2 and mcr-9.**
- **Response 46:**
- 539 Sorry, it was a mistake, we have revised the description in the
- resubmitted manuscript. "two Clade 1 strains co-carried blaKPC-2
- gene and mcr-9 gene which were located on IncFII.pHN7A8._1
- plasmid and IncHI2/IncHI2A plasmid respectively" (Lines 362-364)
- 543 **Point 47:**
- -Line 310: Looks like the three mcr-9 positive strains carried the
- pKPC.CAV1321_1 and not repB_KLEB_VIR plasmid replicon.
- **Response 47:**
- 547 Sorry, it was a mistake, we have revised the description in the
- resubmitted manuscript. "IncHI2/ IncHI2A and pKPC.CAV1321_1
- plasmid replicons were found only in the three mcr-9 positive strains"
- 550 (Lines 364-366)
- 551 **Point 48:**
- Lines 311-313: the same can be said about ST76 strains and

- IncX3_1 plasmid replicon and blaNDM.1_1, blaSHV.12_1,
- 554 **fosA 3, oqxA 1 and oqxB 1.**
- **Response 48:**
- Thanks very much for the reviewer's comments. We have revised the
- description in the resubmitted manuscript.
- 558 "Seven of the eight ST76 strains carried the IncX3 1 plasmid
- replicon which appears to be associated with the presence of several
- resistance genes including blaNDM.1 1, blaSHV.12 1, fosA 3,
- oqxA_1 and oqxB_1 (Additional file 7 Figure S5). However, only
- 562 blaNDM.1 1 gene was found located on the plasmid contigs
- indicating that blaNDM.1_1 gene might be located on the IncX3_1
- 564 plasmid. These data indicated that ST11 and ST76 strains had
- acquired a special plasmid carriage and a corresponding resistance
- gene content pattern respectively." (Lines 367-375)
- 567 **Point 49**:
- Would the authors please comment on Fig 5B at the end of the
- results? From Fig 3D and Fig 5B, it seems that strain xz163
- evolved from a distant parent xz061 and acquired a 4th plasmid
- then further evolved to xz168 and xz181.
- **Response 49:**

- 573 Thanks very much for the reviewer's comments, we have added
- 574 comments on Fig 5B at the end of the results in the revised
- 575 manuscript.
- 576 "Three Clade 1 strains (xz163, xz168 and xz181) had acquired a
- plasmid (IncHI2/IncHI2A) with co-existence of the mcr-9, mphA,
- and bla_{SFO-1} genes. Notably, all of these three strains were isolated
- from the Pediatric Intensive Care Unit and clustered closely in both
- evolutionary and transmission trees. Thus, it was reasonable to infer
- that strain xz163 had evolved from a distant parent xz061 containing
- 3 plasmids and then acquired a 4th plasmid which co-harbored three
- resistance genes and continued to spread to the other two patients in
- the same ward." (Lines 389-397)
- 585 **Point 50:**
- Lines 314-316: Please mention Additional file 8 Figure S6 here.
- **Response 50:**
- Thanks very much for the reviewer's comments, we have added the
- Additional file 9 Figure S7 here.
- 590 "Five and four strains were selected from Clade 1 and Clade 2
- respectively (Fig. 4A, Additional file 9 Figure S7)." (Lines 377-379)
- 592 **Point 51:**
- 593 Lines 371-372: Figures 3D and 3E show the transmission of

- clade 1 but not clade 2, so unless the authors are referring to
 other figures here, would they just mention that these results are
 not shown?
 - **Response 51:**

- 598 Thanks very much for the reviewer's comments, we also have
- 599 conducted the transmission analysis of clade 2, as there were only 4
- 600 isolates of clade 2, which were not sufficient to infer the
- transmission tree by using the TransPhylo software and the results
- were not shown.
- We have revised the description in the resubmitted manuscript.
- 604 "Transmission analysis results showed that Clade 1 strains had
- 605 infected more children and spread to more wards than Clade 2
- strains (results not shown)." (Lines 434-436)

2022

October 19, 2022

Dr. Peng Li Chinese PLA Center for Disease Control and Prevention DONGDA street 20# Beijing China

Re: Spectrum01919-22R1 (Clonal spread of carbapenem-resistant Klebsiella pneumoniae ST11 in Chinese pediatric patients)

Dear Dr. Peng Li:

Your paper has been further revised and all the reviewers suggest other modifications and to address completely previous comments

Thank you for submitting your manuscript to Microbiology Spectrum. When submitting the revised version of your paper, please provide (1) point-by-point responses to the issues raised by the reviewers as file type "Response to Reviewers," not in your cover letter, and (2) a PDF file that indicates the changes from the original submission (by highlighting or underlining the changes) as file type "Marked Up Manuscript - For Review Only". Please use this link to submit your revised manuscript - we strongly recommend that you submit your paper within the next 60 days or reach out to me. Detailed instructions on submitting your revised paper are below.

Link Not Available

Below you will find instructions from the Microbiology Spectrum editorial office and comments generated during the review.

ASM policy requires that data be available to the public upon online posting of the article, so please verify all links to sequence records, if present, and make sure that each number retrieves the full record of the data. If a new accession number is not linked or a link is broken, provide production staff with the correct URL for the record. If the accession numbers for new data are not publicly accessible before the expected online posting of the article, publication of your article may be delayed; please contact the ASM production staff immediately with the expected release date.

The ASM Journals program strives for constant improvement in our submission and publication process. Please tell us how we can improve your experience by taking this quick <u>Author Survey</u>.

Sincerely,

Maria De Francesco

Editor, Microbiology Spectrum

Journals Department American Society for Microbiology 1752 N St., NW Washington, DC 20036 E-mail: spectrum@asmusa.org

Reviewer comments:

Reviewer #1 (Comments for the Author):

The bacterial isolation and AST have been simplified rather than elaborated and explained further. How the bacteria were isolated, at what point identification and antimicrobial susceptibilities were performed are not explained. A review of the electronic medical records should not be explained in the methodology for bacterial isolation and antimicrobial susceptibility. Access to the patients' personal medical files should be explained in the ethical approval as well.

The results of the hand hygiene audit were not provided, instead a detailed explanation of the infection prevention measures was provided. Hand hygiene audit results would indicate the compliance of staff in performing hand hygiene in the wards and

the audits are usually conducted regularly by the infection prevention staff.

Reviewer #2 (Comments for the Author):

Authors improved the quality of the manuscript, adding the experimental and methodological information required by reviewers. Despite this, some formulations and statements remain still inadequate or need to be synthetized. Regarding the style, the final manuscript, in particular some new statements, would benefit from review by a native speaker. A control of the correct use of gene nomenclature (italic, subscript character ect.) is needed.

Reviewer #3 (Comments for the Author):

Would the authors kindly add their response to point 37 to the manuscript?

In the authors' response to point 42, they explained that they carried out Pearson's Chi-squared Test for the strains carrying the blaKPC-2 gene between ST11 and non-ST11 isolates. The authors are kindly requested to add the statistical analysis to the methods section?

Staff Comments:

Preparing Revision Guidelines

To submit your modified manuscript, log onto the eJP submission site at https://spectrum.msubmit.net/cgi-bin/main.plex. Go to Author Tasks and click the appropriate manuscript title to begin the revision process. The information that you entered when you first submitted the paper will be displayed. Please update the information as necessary. Here are a few examples of required updates that authors must address:

- Point-by-point responses to the issues raised by the reviewers in a file named "Response to Reviewers," NOT IN YOUR COVER LETTER.
- Upload a compare copy of the manuscript (without figures) as a "Marked-Up Manuscript" file.
- Each figure must be uploaded as a separate file, and any multipanel figures must be assembled into one file.
- Manuscript: A .DOC version of the revised manuscript
- Figures: Editable, high-resolution, individual figure files are required at revision, TIFF or EPS files are preferred

For complete guidelines on revision requirements, please see the journal Submission and Review Process requirements at https://journals.asm.org/journal/Spectrum/submission-review-process. **Submissions of a paper that does not conform to Microbiology Spectrum guidelines will delay acceptance of your manuscript.** "

Please return the manuscript within 60 days; if you cannot complete the modification within this time period, please contact me. If you do not wish to modify the manuscript and prefer to submit it to another journal, please notify me of your decision immediately so that the manuscript may be formally withdrawn from consideration by Microbiology Spectrum.

If your manuscript is accepted for publication, you will be contacted separately about payment when the proofs are issued; please follow the instructions in that e-mail. Arrangements for payment must be made before your article is published. For a complete list of **Publication Fees**, including supplemental material costs, please visit our website.

Corresponding authors may join or renew ASM membership to obtain discounts on publication fees. Need to upgrade your membership level? Please contact Customer Service at Service@asmusa.org.

Thank you for submitting your paper to Microbiology Spectrum.

1 **REVIEWER n2**

- 2 Authors improved the quality of the manuscript, adding
- 3 experimental and methodological information required by reviewers.
- 4 Despite this, some formulations and statements remain still
- 5 inadequate or need to be synthetized (see "Reviewer New Comment"
- 6 in section "Comments on reviewer requests"). Regarding the style,
- 7 the final manuscript, in particular some new statements, would
- 8 benefit from review by a native speaker.
- 9 A control of the correct use of gene nomenclature (italic, subscript
- 10 character ect.) is needed.

11

12

COMMENTS ON REVIEWER REQUESTS

- 13 **Point 4:**
- 14 Line 110-115: the phrase should be simplified.
- 15 **Response 4:**
- 16 Thanks very much for the reviewer's comments, we have simplified
- the phrase. "MICs were interpreted according to the CLSI (2021)
- 18 guidelines. The electronic medical records of culture-positive
- 19 children were reviewed retrospectively to obtain demographic and
- 20 clinical data." (Lines 110-113)

- 21 **Reviewer New Comment:**
- Line 108: Cancel the dot after the bracket.
- 23 Lines 111-113: Cancel "The electronic medical records of
- 24 culture-positive children were reviewed retrospectively to obtain
- 25 demographic and clinical data.". It's obvious.

26

- 27 **Point 7:**
- Line 124: how reads are quality filtered? Please specify Q30 cut
- off and read length cut off (eventually)
- 30 **Response 7:**
- 31 Thanks very much for the reviewer's comments, we have descripted
- 32 how reads were quality filtered in the revised manuscript.
- 33 "Sequencing reads were quality filtered using the FastQC v0.11.8
- 34 software, adapters and low-quality reads were removed and filtered
- out using Trimmomatic with default parameters." (Line 128-130)

- We also have specified the Q30 cut off and read length cut off in the
- revised manuscript. "The Q30 cut off was set to 85% and the read
- 39 length cut off was set to longer than 100bp." (Lines 130-131)
- **Reviewer New Comment:**
- Lines 130-131: Cancel "The Q30 cut off was set to 85% and the read

- length cut off was set to longer than 100bp.". The first statement is
- 43 sufficient.

- 45 **Point 11:**
- 46 Line 134 and 138: What SNP pipeline do you use as input for
- 47 phylogenesis? Is not clear if snippy o roary. Please clarify.
- **Response 11:**
- 49 Thanks very much for the reviewer's comments, we have added the
- 50 SNP pipeline used as input for phylogenesis in the revised
- 51 manuscript.
- 52 "Initially, SNPs across the whole genome were predicted using
- 53 Snippy v4.6.0, the consensus whole genome alignment was used to
- 54 infer a maximum likelihood phylogenetic tree using Raxml-ng
- v1.0.3 implementing with 1000 bootstrap replicates, GTR+ was
- selected as the best evolutionary model by using Modeltest-ng
- 57 v0.1.7" (Lines 147-151)
- **Reviewer New Comment:**
- 59 Lines 147-151: in order to simplify the text, cancel "across the
- whole genome" (line 147) and "GTR+ was selected as the best
- evolutionary model by using Modeltest-ng v0.1.7" (line 150-151).

63 **Point 21:**

- 64 Line 238: how do you choose this threshold? Do you have
- references? If yes, please add it. It's a very high number of SNPs
- and this high threshold may be misleading. This is a very
- 67 **IMPORTANT aspect**

68 **Response 21:**

- Thanks very much for the reviewer's comments.
- First, we have added description on how the threshold was chosen in
- 71 the revised manuscript.
- 72 "The distribution of the pair-wise SNPs distances among strains was
- visualized as showed in the Additional file 5 Figure S3A, the SNP
- 74 cut-off threshold was determined manually by looking at the graph
- and finding that there were two distinctive groups of genome pairs,
- those with less than 35 SNPs and those with more than 35 SNPs,
- 77 which allowed us to safely infer that two genomes could be
- 78 considered as part of the same transmission cluster if their distance
- 79 in number of SNPs was lower than the 35 SNPs threshold value."
- 80 (Lines 161-168)

- 82 Second, we also have found a reference in which pairs of genomes
- within a distance of 35 SNPs were considered as part of the same
- 84 transmission cluster, and we have added it in the revised manuscript.

- "Pairs of genomes within a distance of ≤35 SNPs (42) were considered as the same transmission cluster." (Lines 283-284)

 Reviewer New Comment:

 The reference you mentioned (42) is appropriate but the threshold
- indicated for related genome clusters in that paper is 16 (not 35), 90 91 which is coherent with other recent multicenter study that proposed 92 to set a threshold for SNP distance in Kp outbreak at 21 (Davis et al, 93 2019; see in bibliography of your reference #42). You can propose a new threshold cut off only if you have strong epidemiological 94 evidences of correlation (e.g. same patient etc) or a strong evidences 95 96 of a longtime evolution that bring to accumulate SNPs in a clone. I suggest you to add also this last reference (Davis et al, 2019) and to 97
- I suggest you to add also this last reference (Davis et al, 2019) and to adjust the threshold value and the results of cluster belonging (with the new threshold, are all your strains part of the genomic cluster?).

100

101

104

Point 22:

- Line 241: how do you calculate that temporal signal was strong?
- 103 **(e.g. Tempest software)**

Response 22:

105 Thanks very much for the reviewer's comments, we have added the

106 description on how the temporal signal was calculated in the revised 107 manuscript. 108 "We used a root to tip regression of sampling dates against genetic diversity in TempEst v1.5.3, optimizing the best fit for the root to 109 maximize the determination coefficient R². The slope of the 110 regression was positive, and the p-value is 0.0006, showing that the 111 genomic data reflect strong temporal signal." (Lines 169-173) 112 **Reviewer New Comment:** 113 Lines 171-173: in order to simplify the text, cancel "The slope of the 114 115 regression was positive, and the p-value is 0.0006, showing that the 116 genomic data reflect strong temporal signal." 117 **Point 24:** 118 Line 277: clarify the reason why you mentioned these genes (this 119 gene are under pression in your opinion?). These observations 120 121 are not well explained. **Response 24:** 122 123 Thanks very much for the reviewer's comments. 124 We have changed "In addition, we identified 5 genes with more than one SNP." with "In this case, a recent population expansion was 125 126 more likely to happen. All the mutations were annotated according to their genome positions, from which 5 genes were identified with more than one mutation, so we further analyzed the mutation type and function of these 5 genes" (Lines 324-328) in the revised the manuscript.

First, after the identification of the major Clade 1 strains, we further analyzed the 152 SNPs found within them, including both the recombination region mutations and point mutations. All the mutations were annotated according to their genome positions, from which 5 genes were identified with more than one mutation, so we further analyzed the mutation type and function of these 5 genes, which turned out that they were associated with virulence and multidrug efflux system.

Second, most of the genes showed negative Tajima's D values (Additional file 6: Figure S4), especially the 5 genes mentioned here which either suggest negative selection or reflect a recent population expansion. In this case, a recent population expansion was more likely to happen, thus it might be hard to infer whether they were under positive or negative selection pressure.

Reviewer New Comment:

- Lines 322-328: in order to simplify the text, substitute only with
- "Most of the genes showed negative Tajima's D values (Additional

- file 6: Figure S4), in particular 5 genes with more than one SNP,
- suggesting a possible negative selection or a recent population
- 151 expansion."

- 153 **Point 26:**
- Line 304: "highly correlated" is not clear, explain better.
- blaKPC-2 is only in this type of plasmids. If yes, supply
- 156 references
- **157 Response 26:**
- Sorry for our inappropriate description, bla_{KPC-2} was not only in this
- 159 type of plasmids and we have revised this description in the
- resubmitted manuscript.
- "All ST11 strains carried the ColRNAI and IncFII plasmid replicons,
- which appears to be associated with the presence of several
- resistance genes" (Lines 355-357)
- 164 **Reviewer New Comment:**
- Lines 359-375: in order to simplify the text, substitute with
- "However, only three genes (blaKPC-2, rmtB, and blaTEM-1B)
- among them were found located on plasmid contigs. In addition, two
- 168 Clade 1 strains co-carried blaKPC-2 gene and mcr-9 gene, which

- were located on IncFII pHN7A8.1 plasmid and IncHI2/IncHI2A
 plasmid respectively. IncHI2/ IncHI2A and pKPC.CAV1321_1
 plasmid replicons were found only in the three mcr-9 positive strains.
 Seven of the eight ST76 strains carried the IncX3_1 plasmid
 replicon which appears to be associated with the presence of several
 resistance genes including blaNDM.1_1, blaSHV.12_1, fosA_3,
 oqxA_1 and oqxB_1 (Additional file 7 Figure S5). However, only
- Line363: Please control if it's correct "IncFII pHN7A8.1". Do you refer to the same plasmid (pHN7A8.1 is a IncFII plasmid?) or two plasmids are present?

blaNDM.1 1 gene was found located on plasmid contigs.

180

181

176

Point 30:

- Line 356-359: this phrase is not clear. Rewrite.
- **183 Response 30:**
- Thanks very much for the reviewer's comments, we have revised the description.

"Based on the spatio-temporal analysis, it was found that the ST11 strains were not the most abundant MLST types in the beginning during our collection period, the number of ST11 strains had increased gradually and eventually it became the most common MLST type." (Lines 423-426)

Reviewer New Comment:

- Lines 423-426: Replace with "Based on the spatio-temporal analysis,
- it was found that the ST11 was not the most abundant ST type at the
- beginning of the collection period, but it increased gradually
- becoming the most common ST type in collected strains"

196

197

198

191

Point 34:

Figure 2C: indicate the meaning of dotted lines in the caption

199 Response 34:

- 200 Sorry for causing your confusion, the dotted lines in Figure 2C were
- meant to highlight the other strains apart from the ST11 between
- which the pairwise number of SNPs were less than 35. For example,
- in the Pediatric Intensive Care Unit (PICU), two ST716 strains were
- 204 enclosed with a dotted line circle since 8 SNPs were identified
- between them indicating that they were also highly clonal.
- The Figure 2 legends had been added with detailed description.
- 207 "Strains apart from the ST11 between which the pairwise number of

- 208 SNPs were less than 35 were enclosed by dotted lines" (Lines
- 209 715-717).
- 210 **Reviewer New Comment:**
- 211 Lines 715-717: Replace with "Dotted lines indicate strains, other
- than ST11, with less than 35 pairwise SNPs"

Response to the reviewers' comments:

Reviewer #1 (Comments for the Author):

Point 1:

The bacterial isolation and AST have been simplified rather than elaborated and explained further. How the bacteria were isolated, at what point identification and antimicrobial susceptibilities were performed are not explained.

Response 1:

Thanks very much for the reviewer's comments, we have elaborated and explained the bacterial isolation and AST as your suggestion.

"The bacteria strains were isolated from clinical specimens, which included sputum, urine, blood, and other samples. Strain identification performed was by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. In vitro antimicrobial susceptibility testing of isolates was analyzed with a VITEK-2 compact system (bioMérieux, Marcy-l'Étoile, France). Antimicrobial susceptibility testing was interpreted in accordance with the Clinical and Laboratory Standards Institute (CLSI), except for tigecycline and colistin, which were interpreted based on the European Committee for Antimicrobial Susceptibility Testing

(EUCAST) criteria." (Lines 116-126)

Point 2:

A review of the electronic medical records should not be explained in the methodology for bacterial isolation and antimicrobial susceptibility.

Response 2:

Done as suggested.

Point 3:

Access to the patients' personal medical files should be explained in the ethical approval as well.

Response 3:

Thanks very much for the reviewer's comments, we have explained the access to the patients' personal medical files in the Ethics approval and consent to participate section.

"A guardian of each child patient provided written informed consent for study participation before enrollment. This study was conducted in accordance with the Declaration of Helsinki. The Clinical Research Ethics Committee of the Affiliated Hospital of Xuzhou Medical University approved the study (XYFY2015-JS016-01), as all samples evaluated in this study were initially collected for

diagnosis during patient care and were thereby obtained without increasing the patients' medical costs and suffering." (Lines 469-476)

Point 4:

The results of the hand hygiene audit were not provided, instead a detailed explanation of the infection prevention measures was provided. Hand hygiene audit results would indicate the compliance of staff in performing hand hygiene in the wards and the audits are usually conducted regularly by the infection prevention staff.

Response 4:

Thanks very much for the reviewer's comments, the hand hygiene compliance rate and correct rate of staff in pediatric ward were 76.9% and 81.64%, respectively.

The hospital had a comprehensive and systematic hand hygiene testing process:

- 1. Formulate the standard instruction for hand hygiene monitoring of medical staff (document number: CML-SOP-3002);
- 2. The department of hospital sense co-ordination, supervision and floor departments regularly carry out hand hygiene, and all samples are sent to microbiology laboratory for cultivation and identification

by professionals;

- 3. Develop environmental hygiene software independently, and trace the results, so as to achieve the purpose of special management and closed-loop monitoring;
- 4. For medical staff in key departments (such as operating rooms and intensive care units), it is mandatory to monitor hand hygiene at least once a month;
- 5. In view of the monitoring results of nosocomial risk, the Department of Nosocomial Infection took the lead and conducted targeted hand hygiene monitoring for the corresponding personnel several times.

Hand hygiene examination is divided into surgical hand disinfection effect monitoring and sanitary hand disinfection effect monitoring (after general medical staff wash their hands). The positive rate of surgical hand disinfection effect monitoring in our hospital from 2018 to 2019 was 2.89%, and that of sanitary hand disinfection effect monitoring was 11.19%.

Reviewer #2 (Comments for the Author):

Point 5:

Authors improved the quality of the manuscript, adding the experimental and methodological information required by reviewers. Despite this, some formulations and statements remain still inadequate or need to be synthetized. Regarding the style, the final manuscript, in particular some new statements, would benefit from review by a native speaker.

Response 5:

Thanks very much for the reviewer's all constructive comments, we have carefully revised our manuscript according to the reviewer's comments and improved the manuscript by a native speaker.

Point 6:

A control of the correct use of gene nomenclature (italic, subscript character ect.) is needed.

Response 6:

Thanks very much for the reviewer's comments, we have carefully examined the use of gene nomenclature in our manuscript according to the reviewer's comments.

" $bla_{\text{KPC-2}}$, $bla_{\text{NDM.1_1}}$, $bla_{\text{NDM-5}}$, $bla_{\text{IMP-4}}$, $bla_{\text{TEM-1B}}$, $bla_{\text{SHV.11_1}}$, $bla_{\text{SHV.12_1}}$,

 $bla_{SHV.155_1}$, bla_{SFO-1} , mcr-9, mphA, rmtB, $fosA_3$, $oqxA_1$ and $oqxB_1$ "

Point 7:

Line 108: Cancel the dot after the bracket.

Response 7:

Done as suggested.

Point 8:

Lines 111-113: Cancel "The electronic medical records of culture-positive children were reviewed retrospectively to obtain demographic and clinical data.". It's obvious.

Response 8:

Done as suggested.

Point 9:

Lines 130-131: Cancel "The Q30 cut off was set to 85% and the read length cut off was set to longer than 100bp." The first statement is sufficient.

Response 9:

Done as suggested.

Point 10:

Lines 147-151: in order to simplify the text, cancel "across the whole genome" (line 147) and "GTR+ was selected as the best evolutionary model by using Modeltest-ng v0.1.7" (line 150-151).

Response 10:

Thanks very much for the reviewer's comments, we have revised the two sentences as suggested.

"Initially, SNPs were predicted using Snippy v4.6.0, the consensus whole genome alignment was used to infer a maximum likelihood phylogenetic tree using Raxml-ng v1.0.3 (35) implementing the GTR+ model with 1000 bootstrap replicates." (Lines 158-161)

Point 11:

The reference you mentioned (42) is appropriate but the threshold indicated for related genome clusters in that paper is 16 (not 35), which is coherent with other recent multicenter study that proposed to set a threshold for SNP distance in Kp outbreak at 21 (Davis et al, 2019; see in bibliography of your reference #42). You can propose a new threshold cut off only if you have strong epidemiological evidences of correlation (e.g. same patient etc) or a strong evidences of a longtime evolution that bring to accumulate SNPs in a clone. I suggest you to add also this last reference (Davis et al, 2019) and to adjust the threshold value and the results of cluster belonging (with

the new threshold, are all your strains part of the genomic cluster?).

Response 11:

Thanks very much for the reviewer's constructive comments.

The pairwise number of SNPs among Clade 1 in our study ranged

from 0 to 29, five strains were excluded from Clade 1 with the

threshold of 21 SNPs. Strains in the reference (Ferrari et al., 2019)

had a time span of 155 days, while our five strains had a time span

of 306 days with the first isolated strain and were isolated at the end

of the collection period, suggesting a possible longer evolution.

In our analysis (Additional file 5 Figure S3), the strains were divided

into two groups, one group had less than 30 SNPs difference among

each other, while the other group had more than 43 SNPs. Thus, we

had reduced threshold and set the value to 30.

We had added the reference as suggested and revised the description

as

"Pairs of genomes within a distance less than 30 SNPs were

considered as the same transmission cluster (Fig. 3B, Additional file

5: Figure S3A)" (Lines 294-296)

Point 12:

Lines 171-173: in order to simplify the text, cancel "The slope of the

regression was positive, and the p-value is 0.0006, showing that the genomic data reflect strong temporal signal.

Response 12:

Done as suggested.

Point 13:

Lines 322-328: in order to simplify the text, substitute only with "Most of the genes showed negative Tajima's D values (Additional file 6: Figure S4), in particular 5 genes with more than one SNP, suggesting a possible negative selection or a recent population expansion."

Response 13:

Done as suggested.

"Most of the genes showed negative Tajima's D values (Additional file 6: Figure S4), in particular 5 genes with more than one SNP, suggesting a possible negative selection or a recent population expansion." (Lines 333-336)

Point 14:

Lines 359-375: in order to simplify the text, substitute with "However, only three genes (bla_{KPC-2} , rmtB, and bla_{TEM-1B}) among them were found located on plasmid contigs. In addition, two Clade

1 strains co-carried $bla_{\text{KPC-2}}$ gene and mcr-9 gene, which were located on IncFII pHN7A8.1 plasmid and IncHI2/IncHI2A plasmid respectively. IncHI2/ IncHI2A and pKPC.CAV1321_1 plasmid replicons were found only in the three mcr-9 positive strains. Seven of the eight ST76 strains carried the IncX3_1 plasmid replicon which appears to be associated with the presence of several resistance genes including $bla_{\text{NDM.1}_1}$, $bla_{\text{SHV.12}_1}$, $fosA_3$, $oqxA_1$ and $oqxB_1$ (Additional file 7 Figure S5). However, only $bla_{\text{NDM.1}_1}$ gene was found located on plasmid contigs.

Response 14:

Done as suggested. (Lines 366-376)

Point 15:

Line363: Please control if it's correct "IncFII pHN7A8.1". Do you refer to the same plasmid (pHN7A8.1 is a IncFII plasmid?) or two plasmids are present?

Response 15:

Sorry for causing your confusion, pHN7A8.1 is a IncFII type plasmid, IncFII pHN7A8.1 was meant to represent the same plasmid, we have revised the sentences as

"IncFII plasmid pHN7A8.1" (Line 369)

Point 16:

Lines 423-426: Replace with "Based on the spatio-temporal analysis, it was found that the ST11 was not the most abundant ST type at the beginning of the collection period, but it increased gradually becoming the most common ST type in collected strains.

Response 16:

Done as suggested. (Lines 423-426)

Point 17:

Lines 715-717: Replace with "Dotted lines indicate strains, other than ST11, with less than 35 pairwise SNPs.

Response 17:

Done as suggested. (Lines 736-737)

Reviewer #3 (Comments for the Author):

Point 18:

Would the authors kindly add their response to point 37 to the manuscript?

Response 18:

Thanks very much for the reviewer's comments, we have added the response to point 37 to the revised manuscript.

"Carbapenems are antimicrobials with proven efficacy in serious infections caused by extended spectrum β -lactamase (*ESBL*) producing bacteria. They possess broad spectrum antibacterial activity which confers protection against most β lactamases such as metallo- β -lactamase (MBL) as well as extended spectrum β -lactamases. Therefore, carbapenems are used as the last resort antibiotics for treating bacterial infections. The World Health Organization listed extended-spectrum β -lactam (*ESBL*)-producing and carbapenem-resistant K. pneumoniae (*CRKp*) as a critical public health threat." (Lines 64-73)

Point 19:

In the authors' response to point 42, they explained that they carried out Pearson's Chi-squared Test for the strains carrying the blaKPC-2 gene between ST11 and non-ST11 isolates. The authors are kindly requested to add the statistical analysis to the methods section?

Response 19:

Thanks very much for the reviewer's comments, we have added the statistical analysis to the revised methods section.

"Pearson's Chi-squared Test was performed for the strains carried the bla_{KPC-2} gene between ST11 and non-ST11 multi-locus sequence

types, the X-squared and *p*-value were calculated to infer statistically significant difference." (Lines 201-204)

October 28, 2022

Dr. Peng Li Chinese PLA Center for Disease Control and Prevention DONGDA street 20# Beijing China

Re: Spectrum01919-22R2 (Clonal spread of carbapenem-resistant Klebsiella pneumoniae ST11 in Chinese pediatric patients)

Dear Dr. Peng Li:

I am pleased to inform you that your paper has been accepted for publication

Your manuscript has been accepted, and I am forwarding it to the ASM Journals Department for publication. You will be notified when your proofs are ready to be viewed.

The ASM Journals program strives for constant improvement in our submission and publication process. Please tell us how we can improve your experience by taking this quick <u>Author Survey</u>.

As an open-access publication, Spectrum receives no financial support from paid subscriptions and depends on authors' prompt payment of publication fees as soon as their articles are accepted. You will be contacted separately about payment when the proofs are issued; please follow the instructions in that e-mail. Arrangements for payment must be made before your article is published. For a complete list of **Publication Fees**, including supplemental material costs, please visit our website.

ASM policy requires that data be available to the public upon online posting of the article, so please verify all links to sequence records, if present, and make sure that each number retrieves the full record of the data. If a new accession number is not linked or a link is broken, provide production staff with the correct URL for the record. If the accession numbers for new data are not publicly accessible before the expected online posting of the article, publication of your article may be delayed; please contact the ASM production staff immediately with the expected release date.

Corresponding authors may join or renew ASM membership to obtain discounts on publication fees. Need to upgrade your membership level? Please contact Customer Service at Service@asmusa.org.

Thank you for submitting your paper to Spectrum.

Sincerely,

Maria De Francesco Editor, Microbiology Spectrum

Journals Department American Society for Microbiology 1752 N St., NW Washington, DC 20036 E-mail: spectrum@asmusa.org

Supplemental Material: Accept